Literature DB >> 16262110

Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction.

Howard C Margolese1, Guy Chouinard, Theodore T Kolivakis, Linda Beauclair, Robert Miller.   

Abstract

OBJECTIVE: Tardive dyskinesia (TD) is the principal adverse effect of long-term treatment with conventional antipsychotic agents. Several mechanisms may exist for this phenomenon. Mechanisms for the lower incidence of TD with atypical antipsychotics also remain to be fully understood. We undertook to explore and better understand these mechanisms.
METHODS: We conducted a comprehensive review of TD pathophysiology literature from January 1, 1965, to January 31, 2004, using the terms tardive dyskinesia, neuroleptics, antipsychotics, pathophysiology, and mechanisms. Additional articles were obtained by searching the bibliographies of relevant references. Articles were considered if they contributed to the current understanding of the pathophysiology of TD.
RESULTS: Current TD vulnerability models include genetic vulnerability, disease-related vulnerability, and decreased functional reserve. Mechanisms of TD induction include prolonged blockade of postsynaptic dopamine receptors, postsynaptic dopamine hypersensitivity, damage to striatal GABA interneurons, and damage of striatal cholinergic interneurons. Atypical antipsychotics may cause less TD because they have less impact on the basal ganglia and are less likely to cause postsynaptic dopamine hypersensitivity.
CONCLUSION: Although the ultimate model for TD is not yet understood, it is plausible that several of these vulnerabilities and mechanisms act together to produce TD. The lower incidence of TD with atypical antipsychotics has helped to elucidate the,mechanisms of TD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16262110     DOI: 10.1177/070674370505000907

Source DB:  PubMed          Journal:  Can J Psychiatry        ISSN: 0706-7437            Impact factor:   4.356


  26 in total

1.  Tardive dyskinesia: therapeutic options for an increasingly common disorder.

Authors:  Leslie J Cloud; Deepti Zutshi; Stewart A Factor
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

Review 2.  Tardive Dyskinesia: Treatment Update.

Authors:  Divya Arya; Tarannum Khan; Adam J Margolius; Hubert H Fernandez
Journal:  Curr Neurol Neurosci Rep       Date:  2019-08-16       Impact factor: 5.081

Review 3.  Genetics of Common Antipsychotic-Induced Adverse Effects.

Authors:  Raymond R MacNeil; Daniel J Müller
Journal:  Mol Neuropsychiatry       Date:  2016-05-20

4.  Dynamics of tyrosine hydroxylase mediated regulation of dopamine synthesis.

Authors:  Poorvi Kaushik; Fredric Gorin; Shireen Vali
Journal:  J Comput Neurosci       Date:  2007-04       Impact factor: 1.621

5.  Effects of discontinuing anticholinergic treatment on movement disorders, cognition and psychopathology in patients with schizophrenia.

Authors:  Julie Eve Desmarais; Linda Beauclair; Lawrence Annable; Marie-Claire Bélanger; Theodore T Kolivakis; Howard C Margolese
Journal:  Ther Adv Psychopharmacol       Date:  2014-12

Review 6.  Abuse of amphetamines and structural abnormalities in the brain.

Authors:  Steven Berman; Joseph O'Neill; Scott Fears; George Bartzokis; Edythe D London
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691

7.  Altered serum levels of glial cell line-derived neurotrophic factor in male chronic schizophrenia patients with tardive dyskinesia.

Authors:  Fei Ye; Qiongqiong Zhan; Wenhuan Xiao; Weiwei Sha; Xiaobin Zhang
Journal:  Int J Methods Psychiatr Res       Date:  2018-06-14       Impact factor: 4.035

8.  Tardive dyskinesia in relation to estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data.

Authors:  Kazunari Yoshida; Robert R Bies; Takefumi Suzuki; Gary Remington; Bruce G Pollock; Yuya Mizuno; Masaru Mimura; Hiroyuki Uchida
Journal:  Schizophr Res       Date:  2014-02-01       Impact factor: 4.939

9.  [Antipsychotic-induced motor symptoms in schizophrenic psychoses-Part 3 : Tardive dyskinesia].

Authors:  D Hirjak; K M Kubera; S Bienentreu; P A Thomann; R C Wolf
Journal:  Nervenarzt       Date:  2019-05       Impact factor: 1.214

10.  Treatment of Tardive Dyskinesia by tetrabenazine, clonazepam and vitamin E.

Authors:  Himanshu Sharma
Journal:  Indian J Psychiatry       Date:  2009-04       Impact factor: 1.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.